nitroglycerin has been researched along with t 1032 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donahue, JK; Lawrence, JH; Marbán, E; Nagata, K | 1 |
| Ikeo, T; Inoue, H; Kikkawa, K; Noto, T; Yano, K | 1 |
2 other study(ies) available for nitroglycerin and t 1032
| Article | Year |
|---|---|
Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adenoviruses, Human; Animals; beta-Galactosidase; Cyclic GMP; Drug Synergism; Endothelial Growth Factors; Gene Transfer Techniques; Genes, Reporter; Genetic Vectors; Guanylate Cyclase; Heart; Humans; Isoquinolines; Lymphokines; Myocardium; Nitric Oxide Donors; Nitric Oxide Synthase; Nitroglycerin; omega-N-Methylarginine; Phosphodiesterase Inhibitors; Piperazines; Purines; Purinones; Pyridines; Rabbits; Sildenafil Citrate; Sulfones; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats.
Topics: Anesthesia; Animals; Blood Pressure; Diltiazem; Dose-Response Relationship, Drug; Ganglionic Blockers; Heart Rate; Isoquinolines; Male; Mecamylamine; Nitroglycerin; Norepinephrine; Phosphodiesterase Inhibitors; Pyridines; Rats; Rats, Wistar; Vasoconstrictor Agents; Vasodilator Agents; Venous Pressure | 2001 |